[go: up one dir, main page]

PA8626101A1 - Sólidos supersaturados estabilizados de drogas lipofílicas - Google Patents

Sólidos supersaturados estabilizados de drogas lipofílicas

Info

Publication number
PA8626101A1
PA8626101A1 PA20058626101A PA8626101A PA8626101A1 PA 8626101 A1 PA8626101 A1 PA 8626101A1 PA 20058626101 A PA20058626101 A PA 20058626101A PA 8626101 A PA8626101 A PA 8626101A PA 8626101 A1 PA8626101 A1 PA 8626101A1
Authority
PA
Panama
Prior art keywords
compound
supersatured
lipophylic
drugs
solids
Prior art date
Application number
PA20058626101A
Other languages
English (en)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8626101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PA8626101A1 publication Critical patent/PA8626101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA COMPOSICION EN LA FORMA DE UN POLVO QUE COMPRENDE UN COMPUESTO CON UNA SOLUBILIDAD EN AGUA A 25°C MENOR QUE lmg/ml, EN LA CUAL EL COMPUESTO ESTA PRESENTE EN LA FORMA DISPERSA A NIVEL MOLECULAR, Y UN VEHICULO QUE TIENE UN AREA SUPERFICIAL ESPECIFICA DE POR LO MENOS 250m²/g. LOS COMPUESTOS SON PREFERIBLEMENTE MOLECULAS ESTEROIDES Y HORMONAS EN GENERAL. EN PARTICULAR, DROSPIRENONA Y VALERATO DE ESTRADIOL. TAMBIEN SE DESCRIBE UNA FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE LA COMPOSICION EN POLVO, Y EL USO DE SILICE AMORFA CON UN AREA SUPERFICIAL ESPECIFICA MAYOR DE 250m/g PARA INHIBIR LA RECRISTALIZACION DE UN COMPUESTO QUE ESTA PRESENTE EN UN SOLVENTE EN UNA CONCENTRACION SUPERSATURADA.
PA20058626101A 2004-03-10 2005-03-10 Sólidos supersaturados estabilizados de drogas lipofílicas PA8626101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04075714 2004-03-10

Publications (1)

Publication Number Publication Date
PA8626101A1 true PA8626101A1 (es) 2006-07-03

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058626101A PA8626101A1 (es) 2004-03-10 2005-03-10 Sólidos supersaturados estabilizados de drogas lipofílicas

Country Status (32)

Country Link
US (1) US8715735B2 (es)
EP (2) EP2087883B1 (es)
JP (1) JP5006185B2 (es)
KR (1) KR101210695B1 (es)
CN (1) CN1984644B (es)
AR (1) AR048500A1 (es)
AT (1) ATE442131T1 (es)
AU (1) AU2005221403B8 (es)
BR (1) BRPI0507342A (es)
CA (1) CA2558582C (es)
CR (1) CR8630A (es)
DE (1) DE602005016551D1 (es)
DK (1) DK1765290T3 (es)
EA (1) EA012746B1 (es)
EC (1) ECSP066902A (es)
ES (2) ES2390406T3 (es)
GT (1) GT200500045A (es)
HR (1) HRP20090614T1 (es)
IL (1) IL177894A0 (es)
MY (1) MY142989A (es)
NO (1) NO20064473L (es)
NZ (1) NZ549793A (es)
PA (1) PA8626101A1 (es)
PE (1) PE20060016A1 (es)
PL (1) PL1765290T3 (es)
PT (1) PT1765290E (es)
RS (1) RS51076B (es)
SI (1) SI1765290T1 (es)
SV (1) SV2005002044A (es)
TW (1) TWI345986B (es)
UY (1) UY28803A1 (es)
WO (1) WO2005087199A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP1898880A2 (en) * 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
US10016442B2 (en) * 2005-06-16 2018-07-10 Allergan Pharmaceuticals International Limited Estrogen compositions for vaginal administration
WO2007128350A1 (en) * 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
ES2602784T3 (es) 2007-02-23 2017-02-22 Gilead Sciences, Inc. Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos
JP5600058B2 (ja) * 2007-04-11 2014-10-01 ファーマシューティカル プロダクションズ， インコーポレイテッド メラトニンタブレットならびに調剤及び使用方法
NZ586666A (en) * 2008-02-13 2012-04-27 Bayer Schering Pharma Ag Estradiol-containing drug delivery system
AU2009224418B2 (en) * 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
HRP20151357T1 (hr) 2008-05-02 2016-01-29 Gilead Sciences, Inc. Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
AU2009303272A1 (en) * 2008-10-10 2010-04-15 Teva Women's Health, Inc. Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
CA2752805A1 (en) * 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
WO2010111397A1 (en) * 2009-03-24 2010-09-30 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
ES2995732T3 (en) 2014-07-21 2025-02-11 Pharmaceutical Productions Inc Solid dosage form composition for buccal or sublingual administration of cannabinoids
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
US11013245B2 (en) * 2017-02-14 2021-05-25 Dsm Ip Assets B.V. Water dispersible formulations
CN110381747A (zh) * 2017-02-14 2019-10-25 帝斯曼知识产权资产管理有限公司 贮存稳定的配制物
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) * 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE69101291T2 (de) 1990-08-30 1994-07-07 Senju Pharma Co Zusammensetzung zur kontrollierten Abgabe von Medikamenten.
DK0492007T3 (da) * 1990-11-29 1995-06-26 Faulding F H & Co Ltd Fremgangsmåde til fremstilling af væskepåfyldte pulvere
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
ATE442147T1 (de) 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
NZ529490A (en) * 2001-06-22 2005-08-26 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
EP1551415B1 (en) 2002-09-05 2009-12-23 Pantarhei Bioscience B.V. Oral pharmaceutical composition comprising 15-hydroxytestosterone and its analogues
DE60330888D1 (de) 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
CA2516096A1 (en) * 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
ES2325591T3 (es) 2004-03-10 2009-09-09 Bayer Schering Pharma Aktiengesellschaft Composiciones que comprenden drospirenona dispersada molecularmente.

Also Published As

Publication number Publication date
KR101210695B1 (ko) 2012-12-11
WO2005087199A2 (en) 2005-09-22
HRP20090614T1 (hr) 2009-12-31
BRPI0507342A (pt) 2007-07-03
EA200601588A1 (ru) 2007-02-27
ATE442131T1 (de) 2009-09-15
CA2558582C (en) 2013-07-16
EP2087883B1 (en) 2012-07-25
CN1984644B (zh) 2010-12-08
PE20060016A1 (es) 2006-02-16
EA012746B1 (ru) 2009-12-30
CA2558582A1 (en) 2005-09-22
DK1765290T3 (da) 2009-11-02
KR20060132999A (ko) 2006-12-22
SV2005002044A (es) 2005-11-04
IL177894A0 (en) 2006-12-31
CR8630A (es) 2007-06-06
WO2005087199A3 (en) 2009-01-15
ES2332229T3 (es) 2010-01-29
TW200600116A (en) 2006-01-01
AU2005221403B8 (en) 2010-01-07
DE602005016551D1 (de) 2009-10-22
PL1765290T3 (pl) 2010-02-26
UY28803A1 (es) 2005-10-31
PT1765290E (pt) 2009-11-23
AR048500A1 (es) 2006-05-03
US8715735B2 (en) 2014-05-06
AU2005221403A1 (en) 2005-09-22
WO2005087199A8 (en) 2007-03-29
NO20064473L (no) 2006-10-10
JP2007528389A (ja) 2007-10-11
SI1765290T1 (sl) 2010-01-29
EP2087883A1 (en) 2009-08-12
EP1765290A2 (en) 2007-03-28
GT200500045A (es) 2005-10-31
ECSP066902A (es) 2006-12-20
TWI345986B (en) 2011-08-01
JP5006185B2 (ja) 2012-08-22
AU2005221403B2 (en) 2009-12-10
US20050207990A1 (en) 2005-09-22
RS51076B (sr) 2010-10-31
MY142989A (en) 2011-02-14
EP1765290B1 (en) 2009-09-09
CN1984644A (zh) 2007-06-20
HK1103660A1 (en) 2007-12-28
NZ549793A (en) 2010-06-25
ES2390406T3 (es) 2012-11-12

Similar Documents

Publication Publication Date Title
PA8626101A1 (es) Sólidos supersaturados estabilizados de drogas lipofílicas
BRPI0819235A2 (pt) Sistema de distribuição transdérmica para hormônios e esteróides
MX2022013619A (es) Compuestos de 2,4-dioxopirimidina que inhiben cd73.
CR6654A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
PE20081114A1 (es) Composiciones farmaceuticas bioadhesivas de agente dual para uso topico
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
AR092497A1 (es) Composicion para formacion de un recubrimiento solido y una union tubular roscada
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
PA8584101A1 (es) Composicion antihelmintica e inyectable mejoradora de crecimiento
AR033221A1 (es) Composicion farmaceutica finamente autoemulsionable
AR053737A1 (es) Formulacion pediatrica de topiramato
CL2012001310A1 (es) Composicion que comprende un oligopeptido ciclo-(arg-gly-asp-dphe-nmeval) que tiene una solubilidad en agua a 20ºc de entre 1 mg/ml y 20 mg/ml y con uno o varios compuestos lipofilicos y/o anfifílicos; proceso para preparar dicha composicion.
NI200900165A (es) Estabilización de vitamina b12
BRPI0511036A (pt) formulações de solução farmacêuticas contendo 17-aag
WO2004101685A3 (en) Metathesis-curable composition with a reaction control agent
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
GT200500306A (es) Compuestos quimicos
SV2006002123A (es) Profarmacos de esteroides con accion androgenica ref. p-sv-78.334/msu
GT200500121A (es) Derivados de sulfamoilbenzoato y sulfamoilaminobenzoato de estradiol.
ES2183200T3 (es) Granulados aplicables por via oral de derivados de hexahidropirazina.
CR20110685A (es) Formulaciones y métodos para mezclas que contienen quitosano sólido